 - Histologically documented adenocarcinoma of the prostate, clinically refractory or resistant to hormone therapy, as assessed by progression following at least one hormonal therapy orchiectomy or luteinizing hormone-releasing hormone LHRH agonist. Subjects must have documented progression following hormonal therapy withdrawal of 4 weeks duration; nilutamide and bicalutamide require 6 weeks withdrawal. 